logo
Leprosy Was Lurking in The Americas Long Before Colonization, Study Finds

Leprosy Was Lurking in The Americas Long Before Colonization, Study Finds

Yahoo2 days ago

Historians have for a long time believed that leprosy was introduced to the Americas by European settlers, but the latest research offers strong evidence to the contrary – suggesting that Indigenous Americans had already been dying of the disease for centuries.
The primary cause of leprosy is a bacterium called Mycobacterium leprae, and the researchers still think this was introduced to America by Europeans. However, it seems a lesser-known culprit was already established by that time.
A new study from an international team of researchers found that another bacterium, Mycobacterium lepromatosis – a less common cause of leprosy infection – was present in the DNA of ancient human remains from Canada and Argentina dating back at least a thousand years.
"This discovery transforms our understanding of the history of leprosy in America," says genomicist Maria Lopopolo, from the Institut Pasteur in France.
"It shows that a form of the disease was already endemic among Indigenous populations well before the Europeans arrived."
The M. lepromatosis bacteria was first discovered in a patient in the US in 2008, and since then it's also been found in red squirrels (Sciurus vulgaris) in the UK. It may well have spread from the US to the UK in the 19th century, the researchers suggest.
In partnership with local Indigenous communities in terms of handling ancestral remains, the researchers analyzed the DNA from a total of 389 ancient and 408 modern human samples. From the results, they put together a genetic family tree of leprosy bacteria.
Even though they were thousands of kilometers apart, the ancient Canadian and Argentinian samples were remarkably genetically similar. That points to a rapid spread of M. lepromatosis across the American continents.
Based on the timeline put together from the DNA, the different strains of M. lepromatosis would have split from a common ancestor more than 9,000 years ago. With that many millennia of evolution under its belt, the team says there are likely even more diverse forms of the bacteria still waiting to be discovered in the Americas.
"We are just beginning to uncover the diversity and global movements of this recently identified pathogen," says biologist Nicolás Rascovan, from the Institut Pasteur. "The study allows us to hypothesize that there might be unknown animal reservoirs."
This all adds a valuable extra layer to our understanding of the history of the Americas, and of leprosy. It gives researchers some incredibly useful data points in terms of the progression and diversification of the disease.
Infectious diseases play an important part in the story of North, South, and Central America, with the arrival of Europeans introducing a host of new pathogens that Indigenous communities weren't biologically prepared for.
Now we know that the leprosy part of the picture is a lot more complicated than we previously realized. Around 200,000 new cases of the disease are reported worldwide every year, though it can now be treated and cured with modern drugs.
"This study clearly illustrates how ancient and modern DNA can rewrite the history of a human pathogen and help us better understand the epidemiology of contemporary infectious diseases," says Rascovan.
The research has been published in Science.
Does Retinol Reverse Signs of Aging? Here's The Science.
Meditation And Mindfulness Have a Dark Side We Often Overlook
A Specific Kind of Birth Control May Increase Stroke Risk

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Europe suffers its largest diphtheria outbreak in 70 years
Europe suffers its largest diphtheria outbreak in 70 years

Yahoo

timean hour ago

  • Yahoo

Europe suffers its largest diphtheria outbreak in 70 years

The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday. Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms. For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization. In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine. That year 362 cases were recorded by the European Centre for Disease Prevention and Control. Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said. A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022. Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated. "The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute. The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added. The exact areas affected by the outbreak remains unclear. But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said. Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public. They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease. That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs. ic-dl/giv

Fast Five Quiz: B-Cell Acute Lymphoblastic Leukemia
Fast Five Quiz: B-Cell Acute Lymphoblastic Leukemia

Medscape

time2 hours ago

  • Medscape

Fast Five Quiz: B-Cell Acute Lymphoblastic Leukemia

Though more common in pediatric populations, B-cell acute lymphoblastic leukemia (B-ALL) affects both children and adults, and it has several genetic subtypes that significantly affect prognosis and treatment decisions. Despite advances in treatment protocols, resistance mechanisms remain a significant challenge. However, some genetic subtypes are associated with more favorable prognosis, and the nuances of this disease are evident in the cascading treatment algorithm recommended by the National Comprehensive Cancer Network (NCCN) for pediatric and adult cases. What do you know about B-ALL? Check your knowledge with this quick quiz. The treatment of B-ALL involves a complex and intensive series of steps. In the induction phase, glucocorticoids are typically used to reduce tumor burden by clearing leukemic cells from the bone marrow. However, point mutations in the NR3C1 gene generally cause resistance to glucocorticoid therapy, which can significantly affect prognosis. Mutations in the CREBBP gene also cause resistance to glucocorticoids DHFR , FPGS , and TYMS genes have been shown to generally cause resistance to methotrexate, not glucocorticoids. Learn more about corticosteroids in B-ALL. In risk stratification for B-ALL, the NCCN notes that having a white blood cell count of > 30 x 109/L is considered a high-risk feature. This is consistent with European guidelines. The NCCN also states that age over 35 years is another high-risk feature for B-ALL. ETP phenotype is a high-risk feature for T-cell acute lymphoblastic leukemia rather than the B-ALL subtype. Hyperdiploidy (a molecular subtype of B-ALL with 51-65 chromosomes) is considered standard risk by the NCCN; data have shown better prognosis for pediatric patients with this subtype. Learn more about risk stratification for B-ALL. TKIs are an important component of induction, consolidation, and maintenance treatment for Ph+ B-ALL. They are recommended by the NCCN for use in conjunction with other drugs, such as corticosteroids, blinatumomab, and inotuzumab ozogamicin (depending on treatment phase and disease severity) and as a treatment post-HCT. They recommend continuing TKI therapy for at least 2 years after HCT, although they note that the 'optimal duration' is unknown for this population. A recent review, however, notes that despite their success in patients with Ph+ B-ALL, approximately 25% of cases will develop resistance to TKIs. Given this possibility, the NCCN notes that clinicians should consider prior TKI intolerance, dose used, BCR::ABL1 mutations, and disease-related features when choosing a specific TKI; they specifically recommend bosutinib, dasatinib, imatinib, nilotinib, or ponatinib as options for TKI therapy. Learn more about Ph+ B-ALL treatments. The DUX4-rearranged subtype of B-ALL is considered to have a favorable prognosis in adolescents and young adults, compared with MEF2D-rearranged, CDX2/UBTF, and IDH1/2; these subtypes generally have inferior prognosis in the same populations (although MEF2D-rearranged has intermediate prognosis in adults). Specifically, DUX4-rearranged B-ALL has been associated with 93% event-free survival and overall survival in pediatric patients, and adolescent and young-adult patients also see longer disease-free survival after complete remission is achieved. Learn more about B-ALL genomics. Several genetic subtypes of B-ALL are associated with varying prognoses, and the outcomes differences seen between pediatric and adult patients can be partly explained by the different subtypes expressed by these populations. Further, new therapies have enabled high survival rates among pediatric patients with B-ALL, with long-term survival of up to 90% in this population. Prognosis for B-ALL in adolescents and adults is comparatively poor. For example, a population-based study reported the following declining survival rates with age: 74% for patients 15-19 years old, 59% for patients 20-39 years old, and 43% for those 40-59 years old. However, the researchers explained that these percentages still demonstrate improvements, as survival rates were overall lower in the 1980s and 1990s. Learn more about B-ALL prognosis.

HIMS Stock Falls Despite Latest Deal to Expand International Footprint
HIMS Stock Falls Despite Latest Deal to Expand International Footprint

Yahoo

time2 hours ago

  • Yahoo

HIMS Stock Falls Despite Latest Deal to Expand International Footprint

Hims & Hers Health, Inc. HIMS announced its agreement to acquire ZAVA, a digital health platform in Europe. The deal, which marks a significant step toward its global expansion, will likely expand HIMS' footprint in the U.K. and will officially launch the company into Germany, France and Ireland, with more markets anticipated soon. The acquisition is expected to close in the second half of 2025, and the deal is expected to be accretive by 2026. Hims & Hers is also planning to introduce a new, personalized dimension of digital health in Europe. Through this, the company aims to provide individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a localized experience, this expansion is also expected to include access to British, German and French healthcare providers in local languages. Hims & Hers expects to share more about the offerings and their rollout in the coming months. The latest acquisition and subsequent expansion in the European markets are expected to significantly solidify HIMS' international footprint. Following the announcement, shares of the company lost nearly 3.6% till yesterday's closing. Historically, the company has gained synergies from its various strategic buyouts. Although the latest deal is likely to be beneficial for HIMS' top-line growth going forward, the stock declined overall. Hims & Hers currently has a market capitalization of $12.25 billion. It has an earnings yield of 1.3%, favorable than the industry's negative yield. In the last reported quarter, HIMS delivered an earnings surprise of 66.7%. Hims & Hers aims to establish its own branded presence, leveraging the ZAVA platform in each of the European markets in the coming quarters and strengthening its digital health offerings on a global scale. It is worth mentioning that ZAVA, which currently serves more than 1.3 million active customers, has an in-house medical team that delivered nearly 2.3 million consultations in 2024 across the U.K., Germany, France and Ireland. Hims & Hers' management expects to leverage ZAVA's established European presence to transform access to care for people across Europe battling widespread, often silent chronic conditions like obesity and depression. Per a report by Grand View Research, the global digital health market was estimated at $288.55 billion in 2024 and is anticipated to witness a CAGR of 22.2% between 2025 and 2030. Factors like the rising incidence of chronic conditions fueling the demand for remote monitoring and management solutions, and technological advancements are likely to drive the market. Given the market potential, the latest buyout is expected to be a significant milestone for Hims & Hers and boost its business globally. In February, Hims & Hers acquired a U.S.-based peptide facility based in California. The buyout will likely enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options. The same month, Hims & Hers acquired an at-home lab testing facility, Sigmund NJ LLC, which is marketed as Trybe Labs. The buyout will likely enable HIMS to support at-home blood draws and more comprehensive whole-body testing. The acquisition is also expected to broaden the company's ability to offer a wide range of personalized treatments, supplements and medications and accelerate the expansion into new clinical categories, including low testosterone, perimenopausal and menopausal support. Shares of the company have surged 154.1% in the past year compared with the industry's 33.8% rise and the S&P 500's gain of 11.4%. Image Source: Zacks Investment Research Currently, HIMS carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are HealthEquity, Inc. HQY, Cencora, Inc. COR and Integer Holdings Corporation ITGR. HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 20.3%. HQY's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 12.4%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. HealthEquity's shares have gained 34.9% against the industry's 21.7% decline in the past year. Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Cencora has rallied 25.3% against the industry's 21.7% decline in the past year. Integer Holdings, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Integer Holdings' shares have lost 0.7% compared with the industry's 13.2% plunge in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store